Dinesh V. Patel Ph.D.
Net Worth

Last updated:

What is Dinesh V. Patel Ph.D. net worth?

The estimated net worth of Dr. Dinesh V. Patel Ph.D. is at least $41,872,095 as of 26 Nov 2024. He owns shares worth $22,955,171 as insider, has earned $9,556,924 from insider trading and has received compensation worth at least $9,360,000 in Protagonist Therapeutics, Inc..

What is the salary of Dinesh V. Patel Ph.D.?

Dr. Dinesh V. Patel Ph.D. salary is $1,040,000 per year as Chief Executive Officer, Pres, Interim PAO, Sec. & Director in Protagonist Therapeutics, Inc..

How old is Dinesh V. Patel Ph.D.?

Dr. Dinesh V. Patel Ph.D. is 68 years old, born in 1957.

What stocks does Dinesh V. Patel Ph.D. currently own?

As insider, Dr. Dinesh V. Patel Ph.D. owns shares in one company:

Company Title Shares Price per share Total value
Protagonist Therapeutics, Inc. (PTGX) Chief Executive Officer, Pres, Interim PAO, Sec. & Director 408,455 $56.2 $22,955,171

What does Protagonist Therapeutics, Inc. do?

Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

PTGX logo
PTGX
Protagonist Therapeutics, Inc.
$56.2

Dinesh V. Patel Ph.D. insider trading

Protagonist Therapeutics, Inc.

Dr. Dinesh V. Patel Ph.D. has made 13 insider trades between 2016-2024, according to the Form 4 filled with the SEC. Most recently he sold 21,480 units of PTGX stock worth $993,450 on 26 Nov 2024.

The largest trade he's ever made was exercising 78,520 units of PTGX stock on 25 Nov 2024. As of 26 Nov 2024 he still owns at least 408,455 units of PTGX stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Common Stock 21,480 $46.25 $993,450
Option
Stock Option (right to buy) 1,727 $21.58 $37,269
Sale
Common Stock 78,520 $46.96 $3,687,299
Option
Common Stock 1,727 $21.58 $37,269
Sale
Common Stock 35,000 $35.19 $1,231,650
Sale
Common Stock 25,000 $28.31 $707,750
Sale
Common Stock 30,000 $31.62 $948,600
Sale
Common Stock 75,000 $20.08 $1,506,000
Option
Common Stock 6,000 $4.21 $25,260
Option
Stock Option (right to buy) 6,000 $4.21 $25,260
Option
Stock Option (right to buy) 20,000 $4.21 $84,200
Option
Common Stock 20,000 $4.21 $84,200
Option
Stock Option (right to buy) 15,742 $4.21 $66,274
Option
Common Stock 15,742 $4.21 $66,274
Option
Common Stock 30,000 $4.21 $126,300
Option
Stock Option (right to buy) 30,000 $4.21 $126,300
Option
Common Stock 34,087 $1.89 $64,424
Option
Stock Option (right to buy) 34,087 $1.89 $64,424
Sale
Common Stock 15,000 $32.15 $482,175
Option
Stock Option (right to buy) 40,000 $4.21 $168,400
Option
Common Stock 40,000 $4.21 $168,400
Option
Stock Option (right to buy) 13,000 N/A N/A
Option
Common Stock 13,000 N/A N/A
Sale
Common Stock 24,846 N/A N/A
Option
Common Stock 10,000 N/A N/A
Option
Stock Option (right to buy) 10,000 N/A N/A
Option
Stock Option (right to buy) 18,344 N/A N/A
Option
Common Stock 18,344 N/A N/A
Purchase
Common Stock 30,000 N/A N/A
Purchase
Common Stock 30,000 N/A N/A
Option
Common Stock 4,000 N/A N/A
Option
Stock Option (right to buy) 4,000 N/A N/A
Sale
Common Stock 10,792 N/A N/A
Sale
Common Stock 2,183 N/A N/A
Sale
Common Stock 10,909 N/A N/A
Option
Stock Option (right to buy) 22,344 N/A N/A
Option
Common Stock 22,344 N/A N/A
Option
Stock Option (right to buy) 13,516 N/A N/A
Option
Common Stock 13,516 N/A N/A
Option
Common Stock 20,000 N/A N/A
Option
Stock Option (right to buy) 20,000 N/A N/A
Option
Stock Option (right to buy) 11,298 N/A N/A
Option
Common Stock 11,298 N/A N/A
Option
Stock Option (right to buy) 8,210 N/A N/A
Sale
Common Stock 8,210 N/A N/A
Option
Common Stock 8,210 N/A N/A
Option
Common Stock 1,790 N/A N/A
Option
Stock Option (right to buy) 1,790 N/A N/A
Sale
Common Stock 1,790 N/A N/A
Option
Stock Option (right to buy) 19,099 N/A N/A
Option
Common Stock 19,099 N/A N/A
Option
Common Stock 20,000 N/A N/A
Option
Stock Option (right to buy) 20,000 N/A N/A
Option
Stock Option (right to buy) 16,362 N/A N/A
Option
Common Stock 16,362 N/A N/A
Option
Common Stock 3,000 N/A N/A
Option
Stock Option (right to buy) 3,000 N/A N/A

Protagonist Therapeutics key executives

Protagonist Therapeutics, Inc. executives and other stock owners filed with the SEC: